TimesSquare Capital Management LLC Purchases 42,015 Shares of Vericel Co. (NASDAQ:VCEL)

TimesSquare Capital Management LLC boosted its position in Vericel Co. (NASDAQ:VCEL) by 7.1% in the fourth quarter, HoldingsChannel reports. The firm owned 632,160 shares of the biotechnology company’s stock after buying an additional 42,015 shares during the quarter. TimesSquare Capital Management LLC’s holdings in Vericel were worth $34,712,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently modified their holdings of VCEL. Creative Planning bought a new position in shares of Vericel during the 3rd quarter valued at approximately $230,000. OLD National Bancorp IN grew its position in shares of Vericel by 23.3% during the 3rd quarter. OLD National Bancorp IN now owns 5,513 shares of the biotechnology company’s stock valued at $233,000 after acquiring an additional 1,043 shares during the period. International Assets Investment Management LLC grew its position in shares of Vericel by 4,126.7% during the 3rd quarter. International Assets Investment Management LLC now owns 634 shares of the biotechnology company’s stock valued at $27,000 after acquiring an additional 619 shares during the period. Mirae Asset Global Investments Co. Ltd. grew its position in shares of Vericel by 22.2% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,773 shares of the biotechnology company’s stock valued at $77,000 after acquiring an additional 322 shares during the period. Finally, PFG Investments LLC grew its position in shares of Vericel by 8.0% during the 3rd quarter. PFG Investments LLC now owns 7,400 shares of the biotechnology company’s stock valued at $313,000 after acquiring an additional 550 shares during the period.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on VCEL. HC Wainwright restated a “buy” rating and set a $60.00 price target on shares of Vericel in a research note on Wednesday, January 15th. Stephens reiterated an “overweight” rating and issued a $65.00 target price on shares of Vericel in a research note on Wednesday, January 15th. Canaccord Genuity Group increased their target price on shares of Vericel from $64.00 to $67.00 and gave the stock a “buy” rating in a research note on Monday, February 3rd. StockNews.com upgraded shares of Vericel from a “sell” rating to a “hold” rating in a research note on Tuesday, December 24th. Finally, Truist Financial increased their target price on shares of Vericel from $61.00 to $67.00 and gave the stock a “buy” rating in a research note on Wednesday, December 18th. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat.com, Vericel currently has an average rating of “Moderate Buy” and a consensus price target of $63.14.

Insider Activity at Vericel

In other Vericel news, insider Jonathan Mark Hopper sold 10,000 shares of the firm’s stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $58.72, for a total value of $587,200.00. Following the sale, the insider now owns 58,371 shares of the company’s stock, valued at $3,427,545.12. This trade represents a 14.63 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Robert L. Md Zerbe sold 2,500 shares of the firm’s stock in a transaction on Wednesday, February 5th. The stock was sold at an average price of $62.50, for a total transaction of $156,250.00. Following the completion of the sale, the director now directly owns 26,595 shares in the company, valued at approximately $1,662,187.50. This trade represents a 8.59 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 22,600 shares of company stock valued at $1,356,072. Insiders own 5.20% of the company’s stock.

Vericel Stock Performance

VCEL stock opened at $57.28 on Wednesday. Vericel Co. has a 52 week low of $39.12 and a 52 week high of $63.00. The firm’s fifty day moving average is $57.82 and its 200 day moving average is $51.41. The firm has a market cap of $2.83 billion, a P/E ratio of 954.83 and a beta of 1.72.

About Vericel

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.